177Lu-EC0800 combined with the antifolate pemetrexed: Preclinical pilot study of folate receptor targeted radionuclide tumor therapy

Molecular Cancer Therapeutics

Volumn 12, Issue 11, 2013, Pages 2436-2445

  Reber, Josefine ^a   Haller, Stephanie ^a   Leamon, Christopher P ^b   Müller, Cristina ^a,c  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

^b Endocyte Inc   (United States)

^c ETH Zurich   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EC 0800; FOLATE RECEPTOR; PEMETREXED; RADIOPHARMACEUTICAL AGENT; SUCCIMER TC 99M; TETRAXETAN FOLATE CONJUGATE LUTETIUM 177; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSIMETRY; DRUG ACCUMULATION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OVARY CANCER; PILOT STUDY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RADIOISOTOPE THERAPY; RENAL PROTECTION; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; COORDINATION COMPLEXES; DRUG EVALUATION, PRECLINICAL; FEMALE; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; KB CELLS; LUTETIUM; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PILOT PROJECTS; RADIOISOTOPES; RADIOPHARMACEUTICALS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887425141     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0170     Document Type: Article

References (50)

1. Zoller F, Eisenhut M, Haberkorn U, Mier W. Endoradiotherapy in cancer treatment-basic concepts and future trends. Eur J Pharmacol 2009;625:55-62.
2. Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012;39 Suppl 1:S103-12.
3. Tomblyn M. Radioimmunotherapy for B-cell non-Hodgkin lymphomas. Cancer Contr 2012;19:196-203.
4. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338: 284-93.
5. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009;13:256-62.
6. Salazar MD, Ratnam M. The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 2007;26:141-52.
7. Dosio F, Milla P, Cattel L. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs 2010;11:1424-33.
8. Pribble P, Edelman MJ. EC145: a novel targeted agent for adenocarcinoma of the lung. Expert Opin Investig Drugs 2012;21:755-61.
9. Holm J, Hansen SI, Hoiermadsen M, Bostad L. A high-affinity folate binding-protein in proximal tubule cells of human kidney. Kidney Int 1992;41:50-5.
10. Sandoval RM, Kennedy MD, Low PS, Molitoris BA. Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy. Am J Physiol Cell Physiol 2004;287:C517-26.
11. Müller C, Reddy JA, Leamon CP, Schibli R. Effects of the antifolates pemetrexed and CB3717 on the tissue distribution of 99mTc-EC20 in xenografted and syngeneic tumor-bearing mice. Mol Pharm 2010;7: 597-604.
12. Müller C, Schibli R, Krenning EP, de Jong M. Pemetrexed improves tumor selectivity of 111In-DTPA-folate in mice with folate receptorpositive ovarian cancer. J Nucl Med 2008;49:623-9.
13. Müller C, Mindt TL, de Jong M, Schibli R. Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folatebased radionuclide therapy. Eur J Nucl Med Mol Imaging 2009;36: 938-46.
14. Müller C, Brühlmeier M, Schubiger AP, Schibli R. Effects of antifolate drugs on the cellular uptake of radiofolates in vitro and in vivo. J Nucl Med 2006;47:2057-64.
15. Müller C, Schibli R, Forrer F, Krenning EP, de Jong M. Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneys. Nucl Med Biol 2007;34:603-8.
16. Müller C, Reber J, Schlup C, Leamon CP, Schibli R. In vitro and in vivo evaluation of an innocuous drug cocktail to improve the quality of folic acid targeted nuclear imaging in preclinical research. Mol Pharm 2013; 10:967-74.
17. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
18. Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta). Oncologist 2004;9:482-8.
19. Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate. Clin Ther 2005;27:1343-82.
20. Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001;6:363-73.
21. Morotti M, Valenzano Menada M, Venturini PL, Mammoliti S, Ferrero S. Pemetrexed disodium in ovarian cancer treatment. Expert Opin Investig Drugs 2012;21:437-49.
22. Monnerat C, Le Chevalier T. Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Ann Oncol 2006;17 Suppl 5:v86-90.
23. Govindan R, Bogart J, Stinchcombe T, Wang X, Hodgson L, Kratzke R, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: cancer and Leukemia Group B trial 30407. J Clin Oncol 2011;29:3120-5.
24. Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, et al. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 2007;13:515-22.
25. Bischof M, Weber KJ, Blatter J, Wannenmacher M, Latz D. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro. Int J Radiat Oncol Biol Phys 2002;52:1381-8.
26. Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 2005; 65:3643-55.
27. Yoshida D, Ebara T, Sato Y, Kaminuma T, Takahashi T, Asao T, et al. Interaction of radiation and pemetrexed on a human malignant mesothelioma cell line in vitro. Anticancer Res 2011;31:2847-51.
28. Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. J Clin Oncol 2007;25:4043-50.
29. Müller C, Vlahov IR, Santhapuram HK, Leamon CP, Schibli R. Tumor targeting using 67Ga-DOTA-Bz-folate-investigations of methods to improve the tissue distribution of radiofolates. Nucl Med Biol 2011; 38:715-23.
30. Müller C, Struthers H, Winiger C, Zhernosekov K, Schibli R. DOTA conjugate with an albumin-binding entity enables the first folic acidtargeted 177Lu-radionuclide tumor therapy in mice. J Nucl Med 2013;54:124-31.
31. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396-401.
32. Müller C, Schubiger PA, Schibli R. In vitro and in vivo targeting of different folate receptor-positive cancer cell lines with a novel 99mTc-radiofolate tracer. Eur J Nucl Med Mol Imaging 2006;33: 1162-70.
33. Hattori Y, Maitani Y. Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase. Cancer Gene Ther 2005;12: 796-809.
34. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006;1:2315-9.
35. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
36. Reber J, Struthers H, Betzel T, Hohn A, Schibli R, Müller C. Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-to-background contrast. Mol Pharm 2012;9: 1213-21.
37. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
38. Mathias CJ, Wang S, Lee RJ, Waters DJ, Low PS, Green MA. Tumorselective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J Nucl Med 1996;37: 1003-8.
39. Forrer F, ValkemaR, Bernard B, Schramm NU, Hoppin JW, RollemanE, et al. In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals. Eur J Nucl Med Mol Imaging 2006;33:1214-7.
40. Leamon CP, Reddy JA, Vlahov IR, Westrick E, Parker N, Nicoson JS, et al. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. Int J Cancer 2007;121: 1585-92.
41. Sanceau J, Poupon MF, Delattre O, Sastre-Garau X, Wietzerbin J. Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-a or interferon-b with ifosfamide. Oncogene 2002; 21:7700-9.
42. Jiang L, Zeng X, Wang Z, Chen Q. Cell line cross-contamination: KB is not an oral squamous cell carcinoma cell line. Eur J Oral Sci 2009;117:90-1.
43. Weyer K, Nielsen R, Petersen SV, Christensen EI, Rehling M, Birn H. Renal uptake of 99mTc-dimercaptosuccinic acid is dependent on normal proximal tubule receptor-mediated endocytosis. J Nucl Med 2013;54:159-65.
44. Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999;59:3671-6.
45. Maity A, McKenna WG, Muschel RJ. The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol 1994; 31:1-13.
46. Yao SL, Akhtar AJ, McKenna KA, Bedi GC, Sidransky D, Mabry M, et al. Selective radiosensitization of p53-deficient cells by caffeine-mediatedactivation f p34cdc2 kinase. Nat Med 1996;2:1140-3.
47. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000;60: 2108-12.
48. Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G2 checkpoint abrogator. Cancer Res 2001;61:8211-7.
49. Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular- structure and biological activity. Mol Pharmacol 1995;48:459-71.
50. Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID. The protoncoupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol 2008;74:854-62.